{1 (2 ML cabotegravir 200 MG/ML Injection) / 1 (2 ML rilpivirine 300 MG/ML Injection) } Pa... — RxCUI 2475417
RxNorm drug concept · Generic pack
RxCUI 2475417
Generic pack · GPCK
● Current RxNorm concept 3 FDA products
3 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2475417
Official name{1 (2 ML cabotegravir 200 MG/ML Injection) / 1 (2 ML rilpivirine 300 MG/ML Injection) } Pack
Concept typeGeneric pack (GPCK)
RxNorm statusCurrent RxNorm concept
Also known ascabotegravir 400 MG / rilpivirine 600 MG Extended Release Kit
FDA products mapped3
Package NDCs mapped3
Reported Medicaid activity (SDUD)57,556 prescriptions · 46 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Cabotegravir and Rilpivirine Injections: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- That's actually the big advantage here — CABENUVA was designed specifically so you don't have to take a pill every single day. The two medicines are formulated to release slowly fr...
- Why do I need injections every month instead of just taking a daily pill?
- Missing an injection is a real concern with CABENUVA. If you go too long between doses, drug levels in your blood can drop low enough that the virus might start to rebound — and it...
- What happens if I miss or delay an injection appointment?
🕸️ Concept Web — How {1 (2 ML cabotegravir 200 MG/ML Injection) / 1 (... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
{1 (2 ML cabotegravir 200 MG/ML Injection) / 1 (2 ML rilpivirine 300 MG/ML Injection) } Pack
RxCUI 2475417 Generic pack · GPCK
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Cabotegravir
2475077IN -
Rilpivirine
1102270IN
-
Cabotegravir
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Cabotegravir Injection
2588076SCDF -
Rilpivirine Injection
2594979SCDF -
Cabotegravir Injectable Product
2475408SCDG -
Rilpivirine Injectable Product
2475412SCDG -
Pack
746839DF -
Injectable Product
1151126DFG
-
Cabotegravir Injection
-
Clinical & branded drugs 4
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
2 ML cabotegravir 200 MG/ML Injection
2594978SCD -
2 ML rilpivirine 300 MG/ML Injection
2594982SCD -
Cabotegravir 200 MG/ML
2475407SCDC -
Rilpivirine 300 MG/ML
2475411SCDC
-
2 ML cabotegravir 200 MG/ML Injection
-
Packs 1
Fixed collections of drugs packaged and sold together, like dose packs.
Showing up to 8 concepts per family — 13 of 13 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
2 ML cabotegravir 200 MG/ML Injection
SCD · 2594978 -
2 ML rilpivirine 300 MG/ML Injection
SCD · 2594982 -
Cabotegravir 200 MG/ML
SCDC · 2475407 -
Rilpivirine 300 MG/ML
SCDC · 2475411 -
Cabotegravir Injection
SCDF · 2588076 -
Rilpivirine Injection
SCDF · 2594979 -
Cabotegravir Injectable Product
SCDG · 2475408 -
Rilpivirine Injectable Product
SCDG · 2475412
Brand-Name Concepts
📦 FDA Products & Package NDCs
3 products · 3 package NDCs
3 package NDCs map to RxCUI 2475417 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 49702-0240-15 | 1 KIT in 1 CARTON (49702-240-15) * 3 mL in 1 VIAL (49702-2... | Cabenuva | ViiV Healthcare Company | 2021-01-21 |
| 49702-0253-15 | 1 KIT in 1 CARTON (49702-253-15) * 2 mL in 1 VIAL (49702-2... | Cabenuva | ViiV Healthcare Company | 2021-01-21 |
| 49702-0266-63 | 1 KIT in 1 CARTON (49702-266-63) * 3 mL in 1 VIAL (49702-2... | Cabenuva | ViiV Healthcare Company | 2025-01-21 |
Observed labelers:
ViiV Healthcare Company (3)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J0741 | Inj, cabote rilpivir 2mg 3mg | 2 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.